Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial

Официальное название

Efficacy and Safety of Neoadjuvant Cadonilimab and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer : a Prospective, Open-label, Single-Arm Phase II Study

Обзор

For locally advanced esophagogastric junction and gastric cancer, neoadjuvant chemotherapy can downstage T and N stage,treated distant micrometastases early , and finally improve the long-term survival. Combination of perioperative PD-1 antibody and chemotherapy for locally advanced esophagogastric junction and gastric cancer could be a novel therapy to increase response rate and reduce recurrence rate.Cadonilimab, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer.

Подробное описание

Locally advanced esophagogastric junction and gastric cancer could be cured by multi-disciplinary therapies including surgery, chemotherapy and radiotherapy. Neoadjuvant chemotherapy can downstage T and N stage, treated distant micrometastases early before local therapy has begun, and finally improve the long-term survival. However, the therapeutic effects remain unsatisfactory.Cadonilimab (AK104), a novel bispecific antibody simultaneously targeting PD-1 and CTLA-4, was designed to boost anti-tumor activity with a favorable safety profile.This study was a single arm, open-label clinical study to evaluate the efficacy and safety of combination with Cadonilimab and Chemotherapy for neoadjuvant treatment of resectable locally advanced adenocarcinoma of the gastro-esophageal junction.

Вмешательства

• Препарат Cadonilimab
  10mg/kg intravenous (IV) every 3 weeks ;
• Препарат Oxaliplatin
  130mg/m², iv drip for 2h, d1, q3w;
• Препарат Capecitabine
  1000mg/m² po, Bid, d1-14, q3w ;

Первичные конечные точки

• Pathologic complete remission rate (pCR) [Срок оценки: up to 1 years]

Вторичные конечные точки (6)

• Major pathologic response，MPR [Срок оценки: up to 1 years]
• R0 resection rate [Срок оценки: up to 1 years]
• Objective Response Rate (ORR) [Срок оценки: up to 3 years]
• Disease Control Rate (DCR) [Срок оценки: up to 3 years]
• 3-year disease-free survival rate of 3year (DFS) [Срок оценки: up to 3 years]
• Overall Survival (OS) [Срок оценки: up to 3 years]

Критерии участия

Критерии включения

• Confirmed gastric and gastroesophageal junction adenocarcinoma by Gastroscopic biopsy histopathological examination.
• Imaging (CT/MRI) and diagnostic laparoscopy confirmed at the stage of cT3-4aN1-3M0(AJCC 8th) .
• Physical condition and organ function allow for for larger abdominal surgery.
• Adequate haematological, renal and liver function.

Критерии исключения

• Patients who have HER2 positive confiemed with IHC3+ or IHC2+ and FISH positive.
• Confirmed at stage IV (AJCC 8th) or unresectable by investigator.
• Prior chemotherapy, radiotherapy, surgery immunotherapy or molecular targeted therapy for gastric cancer.
• Patients are allergic to study medication and its ingredients.
• Known active autoimmune diseases.
• Presence of other uncontrolled serious medical conditions.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Не применимо

Модель

Одна группа

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Китай · 1 центр

• Nanfang Hospital, Southern Medical University — Гуанчжоу

Идентификаторы

NCT: NCT06310473 · NFEC-2023-582

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗